MedTrace Logo

Pembrolizumab in Treating Patients With Relapsed or Refractory Stage IB-IVB Mycosis Fungoides or Sezary Syndrome

NCT02243579 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2019-09-20

Study results available
· View outcomes & findings →

Summary

This phase II trial studies how well pembrolizumab works in treating patients with stage IB-IVB mycosis fungoides or Sezary syndrome that has returned after a period of improvement or has not responded to at least one type of treatment. Monoclonal antibodies, such as pembrolizumab, may block cancer growth in different ways by targeting certain cells.

Conditions

  • Recurrent Mycosis Fungoides and Sezary Syndrome
  • Refractory Mycosis Fungoides and Sezary Syndrome
  • Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v7
  • Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v7
  • Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v7
  • Stage IIIA Mycosis Fungoides and Sezary Syndrome AJCC v7
  • Stage IIIB Mycosis Fungoides and Sezary Syndrome AJCC v7
  • Stage IVA Mycosis Fungoides and Sezary Syndrome AJCC v7
  • Stage IVB Mycosis Fungoides and Sezary Syndrome AJCC v7

Interventions

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Pembrolizumab

Given IV

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • Youn Kim · Cancer Immunotherapy Trials Network

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-15
Primary Completion
2018-01-04
Completion
2019-04-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02243579 on ClinicalTrials.gov